Holen Sie sich die Stockscreener-App
177.08
0.43%
0.75
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$176.33
Offen:
$175.3
24-Stunden-Volumen:
687.36K
Relative Volume:
0.34
Marktkapitalisierung:
$25.98B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.53B
KGV:
16.94
EPS:
10.453
Netto-Cashflow:
$1.85B
1W Leistung:
+1.30%
1M Leistung:
-2.67%
6M Leistung:
+39.52%
1J Leistung:
+18.13%
1-Tages-Spanne:
$175.00
$177.19
1-Wochen-Bereich:
$172.90
$177.29
52-Wochen-Spanne:
$110.03
$185.17
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
177.08 | 25.87B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
1,077.75 | 963.92B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.63 | 500.60B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.98 | 406.30B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
139.18 | 266.48B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
106.78 | 264.21B | 63.90B | 19.05B | 13.05B | 7.5596 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Vontobel Holding Ltd. Sells 18,760 Shares of Biogen Inc. $BIIB - MarketBeat
Pacer Advisors Inc. Acquires 131,258 Shares of Biogen Inc. $BIIB - MarketBeat
Cns Specific Antisense Oligonucleotide MarketForecast - openPR.com
Swedbank AB Grows Stake in Biogen Inc. $BIIB - MarketBeat
Is Biogen Inc Gaining or Losing Market Support?Biogen (NASDAQ:BIIB) - Benzinga
Voya Investment Management LLC Has $8.87 Million Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen to Microsoft: 4 Stocks Morningstar Likes for 2026 - TipRanks
Biogen’s Qalsody posts long-term signal in rare genetic ALS - The Pharma Letter
JAMA Neurology Data Shows Meaningful Effects With Biogen's QALSODY In Long-Term Results - Nasdaq
Macro Review: How Biogen Inc stock performs in high volatility marketsJuly 2025 Weekly Recap & Daily Oversold Bounce Ideas - moha.gov.vn
Biogen (BIIB): Reassessing Valuation After New QALSODY Data, Pipeline Progress and Renewed Growth Optimism - simplywall.st
The Bull Case For Biogen (BIIB) Could Change Following New QALSODY ALS Data And Nasdaq-100 ExitLearn Why - Yahoo Finance
Biogen (BIIB) Stock News Today (Dec. 22, 2025): QALSODY Data, Nasdaq-100 Exit, and Analyst Forecasts - ts2.tech
Biogen : Issues Statement in Response to the Passing of Charles Weissmann, MD, Ph.D., Co-Founder of Biogen - marketscreener.com
Biogen (BIIB) Phase 3 Study Highlights Benefits of QALSODY in ALS Treatment - GuruFocus
Biogen’s QALSODY shows sustained benefits for SOD1-ALS patients - Investing.com India
Biogen's QALSODY Shows Promising Long-Term Effects on Function and Survival in SOD1-ALS, Published in JAMA Neurology - Quiver Quantitative
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS - Biogen
Some ALS patients regained lost function in long-term QALSODY study - Stock Titan
Factor VIII deficiency treatment Market See Incredible Growth 2025-2032 | Baxter, Biogen, Inc., Bayer AG - openPR.com
Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers - Barchart.com
Biogen Stock Forecast for the Week Ahead (Dec. 22–26, 2025): BIIB Near 52-Week High as Leqembi Momentum Meets an Analyst Split - ts2.tech
Wedge Capital Management L L P NC Invests $27.02 Million in Biogen Inc. $BIIB - MarketBeat
Fluent Financial LLC Makes New Investment in Biogen Inc. $BIIB - MarketBeat
Biogen Stock (NASDAQ: BIIB) News and Forecasts for Dec. 20, 2025: RBC’s $210 Target, Leqembi Catalysts, and What Investors Are Watching - ts2.tech
RBC’s Confidence in Leqembi and MS Pipeline Might Change The Case For Investing In Biogen (BIIB) - simplywall.st
Biogen (BIIB) Stock Trades Up, Here Is Why - The Globe and Mail
Biogen Stock (BIIB) After-Hours on Dec. 19, 2025: Why Shares Jumped, Where They Closed After the Bell, and What to Watch Before the Next Market Open - ts2.tech
Is Biogen Inc. stock a bargain at current levelsJuly 2025 Price Swings & Safe Capital Investment Plans - ulpravda.ru
Biogen (NASDAQ:BIIB) Price Target Raised to $165.00 - MarketBeat
Why Biogen Inc. stock remains undervaluedInsider Buying & Daily Stock Momentum Reports - ulpravda.ru
Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth - Pharma Voice
Biogen Inc. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
Biogen stock rated Outperform by RBC Capital with $210 price target - Investing.com Canada
Biogen (BIIB) Set to Advance New Drug BIIB145 from Collaboration - GuruFocus
What margin trends mean for Biogen Inc. stockMarket Sentiment Report & AI Enhanced Trading Alerts - Улправда
BMO Capital Adjusts Price Target on Biogen to $165 From $150, Maintains Market Perform Rating - marketscreener.com
Will Biogen Inc. stock outperform international peersJuly 2025 Intraday Action & Safe Entry Trade Reports - Улправда
Biogen (BIIB): Reassessing Valuation After a Recent 3-Month Share Price Rebound - Yahoo Finance
HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress - Insider Monkey
Is Biogen a Mispriced Opportunity After Renewed Interest in Its Neurology Pipeline? - simplywall.st
BTK Inhibitors Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Will Biogen Inc. stock benefit from sector rotation2025 Macro Impact & Verified Trade Idea Suggestions - Bollywood Helpline
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Disease Trial - marketscreener.com
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List - TradingView — Track All Markets
Pitcairn Co. Acquires Shares of 7,454 Biogen Inc. $BIIB - MarketBeat
Biogen (BIIB) Valuation Check After Positive Neurology Data for Lecanemab and Zorevunersen - simplywall.st
Biogen Inc. (NASDAQ:BIIB) Doing What It Can To Lift Shares - 富途牛牛
Biogen’s New Study on BIIB145: A Potential Game-Changer for MS Treatment? - TipRanks
Alzheimer’s Disease Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Biogen, Eisai, Eli Lilly and Company, AB Science, Alzheon, Inc., Cerecin, BioVie, Eisai Inc - Barchart.com
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
0.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):